[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573570":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":108,"collaborators":22,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":22,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":22,"maxAge":22,"enrollmentInfo":118,"targetDuration":22,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Blueprint Medicines Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Avapritinib","EXPERIMENTAL","Participants who have participated in a Blueprint Medicines sponsored study (the parent study) and continue to benefit from avapritinib.",[13],"Drug: Avapritinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Avapritinib will be administered in accordance with the parent study protocol.",[9],[20,21],"BLU-285","AYVAKIT®",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Blueprint Medicines","CONTACT","617-714-6707","MedInfo@blueprintmedicines.com",[30,43,55,66,77,86,97],{"facility":31,"status":32,"city":33,"state":22,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":22},"Universitair Ziekenhuis Antwerpen (UZA)","RECRUITING","Edegem","2650","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.44504,51.15662,{"lat":41,"lon":40},{"facility":44,"status":32,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":22},"The Hospital for Sick Children","Toronto","Ontario","M5G 1X8","Canada","CA",{"type":38,"coordinates":51},[52,53],-79.39864,43.70643,{"lat":53,"lon":52},{"facility":56,"status":32,"city":57,"state":22,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":22},"A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno","Salerno","84131","Italy","IT",{"type":38,"coordinates":62},[63,64],14.79328,40.67545,{"lat":64,"lon":63},{"facility":67,"status":32,"city":68,"state":22,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":22},"Universitair Medisch Centrum Groningen","Groningen","9700","Netherlands","NL",{"type":38,"coordinates":73},[74,75],6.56667,53.21917,{"lat":75,"lon":74},{"facility":78,"status":32,"city":79,"state":22,"zip":80,"country":70,"countryCode":71,"cosmosGeoPoint":81,"geoPoint":85,"contacts":22},"Erasmus Medisch Centrum","Rotterdam","3015",{"type":38,"coordinates":82},[83,84],4.47917,51.9225,{"lat":84,"lon":83},{"facility":87,"status":32,"city":88,"state":22,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":96,"contacts":22},"Oslo University Hospital","Oslo","0424","Norway","NO",{"type":38,"coordinates":93},[94,95],10.74609,59.91273,{"lat":95,"lon":94},{"facility":98,"status":32,"city":99,"state":22,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":22},"Guys and St Thomas NHS Foundation Trust - St Thomas Hospital","London","SE19RT","United Kingdom","UK",{"type":38,"coordinates":104},[105,106],-0.12574,51.50853,{"lat":106,"lon":105},{"type":109,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100573570","phase-4-avapritinib-rollover-study-100573570",false,"NCT06748001","Avapritinib Rollover Study","An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study","Inclusion Criteria:\n\n* Participated in a Blueprint Medicines sponsored avapritinib clinical study. The Sponsor reserves the right to not roll over patients who have been on drug hold for an extended time period.\n* Completed End of Trial \u002F End of Study (EOT\u002FEOS) visit in the parent study and demonstrated compliance with the parent study requirements.\n* Continue to clinically benefit from treatment with avapritinib.\n* Able to give written informed consent.\n* Agree to continue to use highly effective contraception as defined in this protocol.\n* Female patients of childbearing potential must have negative highly sensitive serum pregnancy test within 20 days before the first dose of avapritinib. Women of nonchildbearing potential do not require this test.\n\nExclusion Criteria:\n\n* Participant is participating in another interventional study.\n* Participant is unwilling or unable to comply with study procedures and study restrictions.\n* Participant is breastfeeding.\n\nOther protocol-defined criteria apply.","ALL",{"count":119,"type":120},60,"ESTIMATED","INTERVENTIONAL",[123],"PHASE4","The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.",[126],"Mastocytosis, Systemic",[128,129,130,131,132],"Indolent Systemic Mastocytosis","ISM","Advanced Systemic Mastocytosis","AdvSM","Rollover study","2026-02-05",{"date":135,"type":136},"2026-02-09","ACTUAL",{"date":138,"type":136},"2024-11-28",{"date":140,"type":120},"2027-12-31",{"name":5,"class":6},7]